| scholarly article | Q13442814 |
| P2093 | author name string | Steven E Hyman | |
| P2860 | cites work | Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication | Q22253031 |
| Shank3 mutant mice display autistic-like behaviours and striatal dysfunction | Q24597501 | ||
| Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription | Q24605428 | ||
| Modelling schizophrenia using human induced pluripotent stem cells | Q24633007 | ||
| Effectiveness of antipsychotic drugs in patients with chronic schizophrenia | Q28273164 | ||
| Effectiveness of adjunctive antidepressant treatment for bipolar depression | Q28295408 | ||
| Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report | Q29615999 | ||
| A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression | Q29617914 | ||
| Optogenetics in neural systems | Q29618164 | ||
| Animal models of neuropsychiatric disorders | Q29619899 | ||
| Human-specific transcriptional networks in the brain | Q30539579 | ||
| De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. | Q33398247 | ||
| Genetic architectures of psychiatric disorders: the emerging picture and its implications | Q33949729 | ||
| Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine | Q34048732 | ||
| Trends in risks associated with new drug development: success rates for investigational drugs | Q34096792 | ||
| Animal models of neuropsychiatric disorders. | Q34158236 | ||
| Effect of psychotropic drugs on the uptake of H3-norepinephrine by tissues | Q34648871 | ||
| Toward Fulfilling the Promise of Molecular Medicine in Fragile X Syndrome | Q34999452 | ||
| Medicine. What are the right targets for psychopharmacology? | Q35047348 | ||
| Can neuroscience be integrated into the DSM-V? | Q36912772 | ||
| Developing treatments for impaired cognition in schizophrenia | Q37969402 | ||
| Functional consequences of mutations in postsynaptic scaffolding proteins and relevance to psychiatric disorders. | Q38006055 | ||
| Learned Helplessness | Q39921518 | ||
| Novartis to shut brain research facility | Q48787775 | ||
| Is pharma running out of brainy ideas? | Q51847289 | ||
| P433 | issue | 155 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 155cm11 | |
| P577 | publication date | 2012-10-01 | |
| P1433 | published in | Science Translational Medicine | Q1573955 |
| P1476 | title | Revolution stalled | |
| P478 | volume | 4 |
| Q54986717 | A robust ex vivo experimental platform for molecular-genetic dissection of adult human neocortical cell types and circuits. |
| Q92447843 | An Innovative Disease-Drug-Trial Framework to Guide Binge Eating Disorder Drug Development: A Case Study for Topiramate |
| Q50101264 | Animal Models in Translational Research: Rosetta Stone or Stumbling Block? |
| Q91997345 | Animal models of PTSD: a challenge to be met |
| Q36772243 | Assessment of adverse effects of neurotropic drugs in monkeys with the "drug effects on the nervous system" (DENS) scale |
| Q57255770 | Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism |
| Q48271076 | Back to basics: luring industry back into neuroscience |
| Q91773699 | Brain Banks Spur New Frontiers in Neuropsychiatric Research and Strategies for Analysis and Validation |
| Q91867564 | Can N-Methyl-D-Aspartate Receptor Hypofunction in Schizophrenia Be Localized to an Individual Cell Type? |
| Q92523500 | Can prospective systematic reviews of animal studies improve clinical translation? |
| Q38392369 | Can proteomics-based diagnostics aid clinical psychiatry? |
| Q35802879 | Challenges in understanding psychiatric disorders and developing therapeutics: a role for zebrafish. |
| Q40237566 | Changing the mindset in life sciences toward translation: a consensus |
| Q26830079 | Circadian rhythms and mood: opportunities for multi-level analyses in genomics and neuroscience: circadian rhythm dysregulation in mood disorders provides clues to the brain's organizing principles, and a touchstone for genomics and neuroscience |
| Q92065355 | Clinical Trials in Alzheimer's Disease: A Hurdle in the Path of Remedy |
| Q35195189 | Closed-loop rehabilitation of age-related cognitive disorders |
| Q50599089 | Commentary: Insights from across diagnostic boundaries: ADHD in the RDoC era--a commentary on Scerif and Baker (2015). |
| Q47239298 | Common genes associated with antidepressant response in mouse and man identify key role of glucocorticoid receptor sensitivity |
| Q90597805 | Developing neuroscience-based treatments for alcohol addiction: A matter of choice? |
| Q30399543 | Don't stress about CRF: assessing the translational failures of CRF1antagonists |
| Q95579834 | Drug discovery in psychopharmacology: from 2D models to cerebral organoids |
| Q46302488 | Drug discovery: Zebrafish uncover novel antipsychotics |
| Q37310536 | Editorial (Thematic Selection: Inflammatory and Immune Responses in Depression). |
| Q38080006 | Future viable models of psychiatry drug discovery in pharma |
| Q39682696 | Gene-set analysis based on the pharmacological profiles of drugs to identify repurposing opportunities in schizophrenia. |
| Q26859474 | Genome-scale neurogenetics: methodology and meaning |
| Q38967700 | Genome-wide association study of lymphoblast cell viability after clozapine exposure. |
| Q29396464 | Human genome-guided identification of memory-modulating drugs |
| Q30363008 | Identification of Distinct Psychosis Biotypes Using Brain-Based Biomarkers |
| Q27008349 | Improving and accelerating drug development for nervous system disorders |
| Q48721089 | Industry withdrawal from psychiatric medication development |
| Q42623009 | Intermittent Access to Ethanol Induces Escalated Alcohol Consumption in Primates |
| Q48176769 | Mental health: depression needs large human-genetics studies |
| Q38960878 | Models of neuromodulation for computational psychiatry |
| Q30432026 | Mouse models of gene-environment interactions in schizophrenia |
| Q38110960 | Neural stem cells as tools for drug discovery: novel platforms and approaches |
| Q50480596 | Neurobiology: learning from marmosets. |
| Q35148225 | Neurofeedback and networks of depression |
| Q38978555 | Neuroscience and the future for mental health? |
| Q36760914 | New Hippocampal Neurons Mature Rapidly in Response to Ketamine But Are Not Required for Its Acute Antidepressant Effects on Neophagia in Rats. |
| Q37607004 | New paradigms for treatment-resistant depression |
| Q51438275 | Nociceptin Receptor as a Target to Treat Alcohol Use Disorder: Challenges in Advancing Medications Development. |
| Q38826903 | Opportunities and challenges in modeling human brain disorders in transgenic primates |
| Q45233687 | Opposing roles of primate areas 25 and 32 and their putative rodent homologs in the regulation of negative emotion |
| Q46310313 | Organoid technology for brain and therapeutics research |
| Q90600109 | Oxytocin Enhances an Amygdala Circuit Associated With Negative Symptoms in Schizophrenia: A Single-Dose, Placebo-Controlled, Crossover, Randomized Control Trial |
| Q38683538 | Oxytocin effects in schizophrenia: Reconciling mixed findings and moving forward |
| Q35107323 | Pathway analyses implicate glial cells in schizophrenia |
| Q36594394 | Pathways to new drug discovery in neuropsychiatry |
| Q37255533 | Pharmaceutical Innovation in the Treatment of Schizophrenia and Mental Disorders Compared with Other Diseases |
| Q36109996 | PhenoPredict: A disease phenome-wide drug repositioning approach towards schizophrenia drug discovery |
| Q89983282 | Post-translational protein modifications in schizophrenia |
| Q38268791 | Postdependent state in rats as a model for medication development in alcoholism |
| Q90029576 | Prebiotics and probiotics for depression and anxiety: A systematic review and meta-analysis of controlled clinical trials |
| Q40965698 | Psychiatric drug development: diagnosing a crisis |
| Q44884838 | Public-private partnerships to revitalize psychiatric drug discovery |
| Q90214267 | Redirecting the revolution: new developments in drug development for psychiatry |
| Q57316758 | Rediscovering the value of families for psychiatric genetics research |
| Q90427486 | Reduced GluN1 in mouse dentate gyrus is associated with CA3 hyperactivity and psychosis-like behaviors |
| Q57475754 | Resilience priming: Translational models for understanding resiliency and adaptation to early life adversity |
| Q37379464 | Revitalizing psychiatric therapeutics |
| Q40446474 | Schizophrenia research in 2013: are we making progress? |
| Q91794197 | Sleep as a translationally-relevant endpoint in studies of autism spectrum disorder (ASD) |
| Q91610081 | Slow-release delivery enhances the pharmacological properties of oral 5-hydroxytryptophan: mouse proof-of-concept |
| Q30366697 | Targeting Functional Biomarkers in Schizophrenia with Neuroimaging. |
| Q28074803 | The "Vulnerability" of Psychiatric Research Participants: Why This Research Ethics Concept Needs to Be Revisited |
| Q48305886 | The Corticotropin Releasing Factor Receptor 1 in Alcohol Use Disorder: Still a Valid Drug Target? |
| Q37666098 | The Genetics-Driven Revival in Neuropsychiatric Drug Development. |
| Q35754731 | The NIMH experimental medicine initiative |
| Q38848288 | The Need for Treatment Responsive Translational Biomarkers in Alcoholism Research |
| Q58556540 | The Role of Precision Medicine in Child Psychiatry: What Can We Expect and When? |
| Q39423428 | The current development of CNS drug research |
| Q50418526 | The daunting polygenicity of mental illness: making a new map. |
| Q36677600 | The diminished pipeline for medications to treat mental health and substance use disorders |
| Q47601684 | The microbiome as a novel paradigm in studying stress and mental health. |
| Q28236333 | The neurocircuitry of illicit psychostimulant addiction: acute and chronic effects in humans |
| Q35190746 | The place of psychotherapy in contemporary psychiatry |
| Q38629117 | The promise and pitfalls of intranasally administering psychopharmacological agents for the treatment of psychiatric disorders |
| Q38802467 | The promises and challenges of human brain organoids as models of neuropsychiatric disease |
| Q90285681 | The research domain criteria framework in drug discovery for neuropsychiatric diseases: focus on negative valence |
| Q38992286 | The road to precision psychiatry: translating genetics into disease mechanisms. |
| Q50623386 | The unconscionable gap between what we know and what we do. |
| Q91516614 | Translating the promise of 5HT4 receptor agonists for the treatment of depression |
| Q37275071 | Translation: screening for novel therapeutics with disease-relevant cell types derived from human stem cell models |
| Q37171853 | Translational Assessment of Reward and Motivational Deficits in Psychiatric Disorders |
| Q38370696 | Translational psychiatry--light at the end of the tunnel. |
| Q47561695 | Tranylcypromine Causes Neurotoxicity and Represses BHC110/LSD1 in Human-Induced Pluripotent Stem Cell-Derived Cerebral Organoids Model |
| Q37384323 | Twenty-five years of progress: the view from NIMH and NINDS |
| Q28083512 | What Have Mass Spectrometry-Based Proteomics and Metabolomics (Not) Taught Us about Psychiatric Disorders? |
| Q48800850 | White matter injuries induced by MK-801 in a mouse model of schizophrenia based on NMDA antagonism |
| Q92217485 | Why we need nonhuman primates to study the role of ventromedial prefrontal cortex in the regulation of threat- and reward-elicited responses |
| Q30369007 | Zebrafish behavioral profiling identifies multitarget antipsychotic-like compounds. |
| Q30773565 | σ1 receptor ligands control a switch between passive and active threat responses |
Search more.